Skip to content
MARKETS / NYSE / SOLV
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Solventum Corp. SOLV

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$8.3B
▲ 0.9% YoY
$1.6B
▲ 224.8% YoY
$-10.0M
▼ 101.2% YoY
In brief

What this company does

Solventum Corporation develops, manufactures, and commercializes healthcare solutions that draw on material science, data science, and digital capabilities. It sells its products in more than 90 countries. It employed approximately 20,000 people, including about 10,000 in the United States and about 2,000 in Germany. It is organized into three reportable operating business segments aligned with the markets it serves. Its MedSurg segment, which accounted for 57.9% of 2025 total sales, provides negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes. Its Dental Solutions segment, which accounted for 16.2% of 2025 total sales, provides dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. Its Health Information Systems segment, which accounted for 16.3% of 2025 total sales, provides healthcare systems with software solutions including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms.

Written from the business description in SOLVENTUM CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 8.3B
Revenue, FY2025 · full 4-year series below
Revenue $B Net income $B
FY2025 · Revenue 8.3 · Net income 1.6
4B8B2022202320242025
Compound annual growth
+0.8%
+5.0%
+4.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
19 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 26.2% · Net 18.7%
10%20%2022202320242025
ROE
FY2025 · ROE 38.9%
10%20%30%2022202320242025

Each USD of equity produced 39 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF -0.0
0.8B1.6B2022202320242025

Total assetsUSD 14.3B
EquityUSD 5.0B
CashUSD 878.0M
Gross debtUSD 5.0B
Net debtUSD 4.2B
Current ratio1.23×

Net debt stands at 82% of equity.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022
Revenue $B8.38.38.28.1
Operating income $B2.21.01.71.7
EBITDA $B2.71.62.32.3
Income tax $B0.20.10.30.3
Net income $B1.60.51.31.3
Free cash flow $B−0.00.81.61.4
EPS, diluted $8.882.767.797.78
Dividend / sh $····
Payout %····
ROE %38.96.611.511.4
Shares out B0.170.170.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 14 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2022

Share this section

Download image